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BACKGROUND 
The concept of gene therapy evolved from the initial observation
that certain diseases are caused by the inheritance of a single func-
tionally defective gene. Theoretically, diseases caused by a genetic
defect could be treated and potentially cured by the insertion and
expression of a normal copy of the mutant or deleted gene in host
cells. The idea of gene replacement therapy represents the basic
framework behind therapeutic approaches to monogenic disease.
Following early gene therapy efforts targeting inherited diseases
such as adenosine deaminase deficiency and cystic fibrosis, it
became obvious that the limited efficiency of gene transfer that
could be accomplished with the existing vectors, would make
treatment of monogenic hereditary diseases by using gene transfer
approaches extremely challenging. As a result, the evolution of
clinical gene transfer efforts has taken a somewhat unexpected
course. 
To date, almost two-thirds of the gene therapy clinical trials
(more than 300 trials worldwide) are focusing on cancer. One
important motivation that underlies the shift has been the evolu-
tion of cancer gene therapy approaches that are less affected by the
technical limitations complicating treatment of inherited genetic
diseases. These approaches attempt to increase tumour cell
immunogenicity and/or enhance killing via gene replacement, or
suicide gene transfer and, opposite to the manipulations directed
toward overcoming metabolic disorders, do not require sustained
and tightly regulated gene expression in target cells (Roth and
Cristiano, 1997; Anklesaria, 2000). 
Nevertheless, since the development of the first cancer gene
therapy clinical trials in the early 1990s, one major criticism has
focused on the concern that more scientific proof was necessary
prior to gene transfer approaches being introduced to the clinic
(Crystal, 1995). On the other hand, the suboptimal ability of
animal models to accurately predict safety and efficacy of gene
transfer in humans made clinical trials necessary in order to first
and foremost establish safety and vector kinetics, with efficacy
being a secondary endpoint. 
During the last 2 years, an impressive amount of public atten-
tion has been focused on gene therapy as a result of two events.
Although neither of them occurred in cancer gene therapy clinical
trials, they definitely have affected the evolution of clinical stan-
dards in the field of cancer gene therapy. 
The first event was the death of an adult patient with ornithine
transcarbamylase (OTC deficiency) in a clinical trial at the
University of Pennsylvania. In this study, either female carriers or
males with a mild form of the disease were treated via the hepatic
artery with escalating doses of a non-replicating adenovirus,
containing the gene for ornithine transcarbamylase. An 18-year-
old patient in the sixth (highest) dose cohort who received an
approximate total of 4 × 1013 viral particles died 4 days after treat-
ment. Initial investigation of the events leading to the patient’s
death concluded that the probable cause of death was acute respi-
ratory distress syndrome, resulting from an inflammatory response
possibly secondary to activation of innate immunity (Marshall,
1999). This event resulted in media frenzy and an outpouring of
negative commentary in the lay press, regarding the potential risks
associated with gene transfer, the apparent oversight, and the
suboptimal requirements for recording and reporting serious
adverse events in gene therapy trials. Although a good deal of the
discussion was based on misunderstanding or misinformation on
the incidence of adverse events in phase I clinical studies and the
already existing reporting requirements, still some critical lessons
have been emphasized: rules and guidelines for conducting
preclinical experiments, clinical trials, and quality assurance
testing of materials, including gene delivery vectors, should be
reinforced. In addition, as the field of gene therapy evolves, there
is a major need to compose data regarding efficiency of gene
delivery, safety and toxicity in accessible databases so that this
already accumulated information can be translated into useful
knowledge for all investigators. 
On the positive side, however, the first unequivocal demonstra-
tion of clinical gene transfer efficacy was achieved by ex vivo
treatment of 2 infants, using a retrovirus to deliver the γ C cytokine
receptor gene to treat one of the most severe immunodeficiencies,
the SCID-X1 disease (Cavazzana-Calvo et al, 2000). This success
is the first significant demonstration of long-term clinical benefit
(lasting nearly one year at the time of the original report) that
resulted from gene delivery in human trials. Despite the fact that
the actual duration of the clinical benefit is not clear yet, this result
has generated great optimism regarding the eventual realization of
clinical benefits from gene delivery. 
This review will expand on lessons learned during the last 10 years
from gene transfer clinical trials in the treatment of cancer, mainly
focusing on safety and vector kinetics. Discussion on efficacy will be
limited to pertinent demonstrations of general principles rather
than an exhausting description of detailed results. 
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SAFETY IN CANCER GENE THERAPY CLINICAL
TRIALS 
Several clinical trials during the last decade have proven the
safety of intratumoural administration of a variety of vectors,
both replicating and non-replicating for different therapeutic
transgenes; among them retroviral, adenoviral vectors, vaccinia
virus, and DNA/liposome complexes. Sites of administration
include skin and subcutaneous tumour deposits, lymph nodes
(Stopeck et al, 1997), the central nervous system (Ram et al, 1997;
Klatzmann et al, 1998; Packer et al, 2000), prostate gland
(Herman et al, 1999; Sweeney and Pisters, 2000), and a variety
of other intra-abdominal and thoracic visceral organs such as
liver and lungs (Rubin et al, 1997; Galanis et al, 1999). Most of
these injections were performed under direct CT or ultrasound
guidance, while bronchoscopic administration has also been
employed for endobronchial lesions (Roth et al, 1996) and
administration through endoscopic ultrasound for pancreatic
lesions (Mulvihill et al, 2001). 
Toxicity in these early studies appears to be related mainly to
the injection procedure with up to 50% of the patients experi-
encing mild pain and discomfort at the injection site when gene
transfer is performed under CT or US guidance (Galanis et al,
1999). The incidence of pneumothorax after CT-guided or bron-
choscopic delivery of an adenoviral vector encoding p53 in
patients with advanced NSCL cancer varied from 7% (6/84 injec-
tions) (Swisher et al, 1999) to 21% (13/61 injections) (Swisher
et al, 2000) in different clinical trials. 
Vector-related toxicity was dependent, as expected, on the
type of the vector, the dose, and the site of administration. For
example, intracranial administration of retrovirus-producing
fibroblasts into the resection cavity of patients with recurrent
glioblastoma multiforme has resulted in subarachnoid haemor-
rhage and aseptic ventriculitis in 2/12 patients (Klatzmann et al,
1998). Fever and chills appeared to be common side effects after
administration of non-replicating adenoviruses such as an aden-
ovirus encoding the p53 gene into locally recurrent head and
neck tumours (Clayman et al, 1998) or in the prostate gland
(Sweeney and Pisters, 2000) of patients with local recurrence
after radiation therapy. They were related to the viral dose and
more common when doses > 1010 pfu were employed.
Intratumoural injections of recombinant vaccinia virus encoding
GMCSF in patients with dermal or subcutaneous metastasis from
cutaneous melanoma resulted in development of mild flu-like
symptoms that resolved within 24 hours and local inflammation
with pustule formation when doses > 107 pfu were employed
(Mastrangelo et al, 1999). 
Certain administration sites such as the peritoneal cavity impose
additional challenges. Intraperitoneal administration of viral
vectors can result in sterile peritonitis; 3/12 patients developed this
reaction as evidenced by patient discomfort, fever, increased peri-
toneal fluid cell counts, and negative bacterial cultures, after
receiving a retroviral vector encoding for BRCA1 (up to a total
dose of 1010 viral particles) (Tait et al, 1997). Similarly, inflamma-
tory infiltrate was observed after intrapleural administration of an
adenoviral vector encoding HSV-tk (Molnar-Kimber et al, 1998). 
Less frequently, side effects have been attributed to therapeutic
transgenes such as mild flu-like symptoms seen after intra-
tumoural administration of IL-2/cDNA/DMRIE/DOPE lipid
complex (Galanis et al, 1999) and to the prodrug used in suicide
approaches (i.e. LFT elevation as a result of ganciclovir) (Sterman
et al, 1998). Of note, large doses of plasmid DNA (up to 4 mg per
dose in a repeat administration schedule) appear to be well toler-
ated, without evidence of development of anti-DNA antibodies
(Daniels and Galanis, 2001). 
Nevertheless, advanced cancer is predominately a systemic
disease. Therefore, with the exception of immunotherapeutic
approaches attempting in situ vaccination, as well as gene delivery
to treat certain tumour types such as brain tumours and ovarian
cancer that rarely metastasize, it soon became obvious that
improved gene transfer efficiency and systemic administration of
gene transfer vectors would be necessary in order to improve the
clinical applicability of gene transfer technology. For this to
happen, a dogma of the early clinical days of gene transfer
opposed to the use of replicating vectors had to be overcome. In
addition, the importance of delivering gene transfer vectors
systemically (intravenously or intra-arterially), became obvious
(Russell, 1994). 
Most clinical experience with replicating viruses has been
gained with the E1B attenuated adenovirus ONYX-015 (Bishoff
et al, 1996) that appears to selectively, but not exclusively (Goodrum
and Ornelles, 1998; Rothman et al, 1998), replicate in cells with
malfunctioning p53. Clinical trials with this agent have been
completed in patients with head and neck cancer (Khuri et al, 2000),
pancreas (Mulvihill et al, 2001), ovarian cancer (Vasey et al, 2000),
and GI malignancies metastatic to the liver (Bergland et al, 1998).
Other replicating viruses recently introduced to the clinic include the
provisionally replicating adenovirus CN207 in which the expres-
sion cassette is driven by PSA promoter/enhancer elements and,
therefore, it can selectively replicate in prostate tissue (Rodriguez
et al, 1997). A recently completed phase I/II trial in patients with
locally recurrent prostate cancer, after failure of radiation, showed
that doses of up to 1013 particles of the CN207, administered using
brachytherapy techniques, appeared to be safe, although biochem-
ical (PSA) responses were observed in a minority of patients
(Simons et al, 2000). Additionally, a double mutant herpes simplex
virus engineered with deletion of both copies of γ 34.5 gene and a
lacZ insertion disabling the U39 gene (encoding the large subunit
of the viral ribonucleotide reductase), has been administered
stereotactically in patients with recurrent gliomas at doses up to
3 × 109 pfu without any significant toxicity, including encephalitis,
being encountered (Market et al, 2000). Other replicating viruses
currently in clinical trials include the reovirus, a virus that repli-
cates in malignant cells with an activation in the ras signaling
pathway (Coffey et al, 1998) and the animal pathogen Newcastle
disease virus (Pecora et al, 2001). 
As it pertains to systemic administration of viral vectors, the
clinical work has been focused mainly on adenoviruses, both repli-
cating and non-replicating. Hepatic artery administration of a non-
replicating adenovirus encoding the tumour suppressor gene
p53 showed that very high adenoviral doses of approximately
7.5 × 1013 particles could be associated with hypotension (Venook
et al, 1998). In contrast, lower doses of both the non-replicating
p53 adenovirus (approximately 2.5 × 1013 particles) and 2 × 1012
particles of the replicating adenovirus ONYX-015, administered
through the hepatic artery, were well tolerated (Reid et al, 2000).
The most common side effects associated with the administration
of the ONYX virus include mild constitutional symptoms
and reversible LFT elevation. Intravenous administration of
ONYX-015 in doses up to 2 × 1012 viral particles was also well
tolerated except for mild to moderate constitutional symptoms
(Nemunaitis, personal communication). 1434 E Galanis and S Russell 
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VECTOR KINETICS IN CANCER GENE THERAPY
CLINICAL TRIALS 
In a minority of reported trials, not only issues pertaining to safety,
but also kinetics of the vectors employed, were addressed. A phase
I/II trial of intratumoural administration of a p53 encoding aden-
ovirus (Adp53) in patients with recurrent head and neck cancer
(Clayman et al, 1998) showed that Adp53 DNA was detected in
blood by PCR by 30 minutes after Adp53 injection and gradually
eliminated over the next 48 hours. Cytopathic effect (CPE) assays
performed in patients treated at 3 × 1010 and 1011 pfu (the highest 2-
dose levels) showed that viable Adp53 was present in blood at the
highest levels 30 minutes after intratumoural injections, decreased
at a rate of 2 – 4 orders of magnitude by 90 minutes and further
decreased to very low or undetectable titres by 24 hours to be
completely eliminated by 48 hours after injection. Ad p53 was
detected in the urine from some patients who received doses of
3 × 109 pfu or greater and was present in urine from all patients
who received doses of 3 × 1010 pfu or greater. Adp53 detection in
the urine started within one day of the beginning of p53 injections
and was detected through repeat treatment courses. The highest
titre detected in the urine was 106 pfu/0.5 ml. Urine was free of
Adp53 within 3 – 17 days of the last Adp53 injection. 
Adp53 was also detected in the sputum and/or saliva samples of
6 high-dose patients tested. As with urine samples, Adp53 was
detected within one day of injection, was present for several days
after the last injection of the virus, and was cleared to background
levels within 7 days. Similarly, an HSV-tK adenovirus was detected
in a dose-dependent manner in the urine of all patients after
intraprostatic administration (Herman et al, 1999). 
When the replicating adenovirus ONYX-015 was administered
intrahepatically, 2 peaks of viral titres were detected by PCR in the
peripheral blood; one 30 minutes after intra-arterial administra-
tion; and the second, 3 days later, consistent with viral replication
(Reid et al, 2000). Of note, in all adenoviral trials, the level of
neutralizing antibodies appeared to increase significantly after
administration of the virus within 3 – 4 weeks. Antibody titre
however, did not appear to correlate with adenoviral dose or
course of treatment and did not prevent the expression of thera-
peutic transgene after intratumoural administration or viral replica-
tion after intra-arterial administration (Clayman et al, 1998; Reid
et al, 2000). 
A significant public health issue relates to the exposure of
health-care providers and family members to potentially harmful
viral vectors. This has been only minimally or inadequately
addressed in most clinical trials. In one study of intratumoural
administration of adenoviral vectors, 2 health providers with the
greatest risk of exposure were tested. No elevation of neutralizing
antibodies was observed in their serum, and neither serum nor
urine contained infectious p53 particles or Adp53 DNA (Clayman
et al, 1998). 
EFFICACY 
There are occasional reports of efficacy in cancer gene therapy clin-
ical trials employing a variety of approaches including immuno-
therapy, tumour suppressor gene reconstitution, and prodrug
activation therapy. 
Examples of clinical efficacy mediated through immunothera-
peutic gene transfer approaches include partial responses observed
in 2/14 renal cell carcinoma and 1/16 melanoma patients after
intratumoural administration of IL-2 gene DMRIE/DOPE lipid
complex (Galanis et al, 1999), responses of the injected lesions in
up to 20% of the patients when the HLA-B7 gene in combination
with the cationic lipid complex DMRIE/DOPE was administered
intratumourally in melanoma patients (Hersch and Stopeck, 1997),
and a partial response achieved in a patient with metastatic renal
cell carcinoma to the lungs when an autologous vaccine consisting
of patients’ own tumour cells transduced with a retroviral vector
encoding GMCSF was employed (Simons et al, 1997). Generally,
immunotherapy approaches are less affected by the limited effi-
cacy of gene transfer as compared to other gene transfer strategies,
since transfection or transduction of a relatively small percentage
of cancer cells may be still adequate in order to elicit immunologic
response. 
Using a ‘gene-replacement’ approach, transient local disease
control has been observed after bronchoscopic administration of a
p53 retroviral vector in 3/8 patients (Roth et al, 1996). In a subse-
quent phase I study of bronchoscopic or CT-guided intratumoural
injection of a non-replicating adenovirus encoding p53, 2/28
patients exhibited partial responses (Swisher et al, 1999). Similar
results were obtained with the use of p53 adenovirus in patients
with head and neck cancer (Clayman et al, 1998). Of note, the
presence of circulating neutralizing antibodies did not preclude
gene transfer or antitumour activity, a principle that has been
demonstrated not only for intratumoural, but also for intrapleural
(Molnar-Kimber et al, 1998) and intrahepatic administration of
adenoviral vectors (Venook et al, 1998). 
As it pertains to prodrug activation therapy, intracranial stereo-
tactic administration of retroviral vector producer cells (VPCs)
producing a Maloney Leukemia virus vector coding for the HSV-tk
gene, followed by treatment by ganciclovir, resulted in 5 objective
responses out of 15 patients with recurrent brain tumours who had
the VPCs introduced stereotactically (Ram et al, 1997). This type
of encouraging data led to a large multinational phase III study in
newly diagnosed patients with glioblastoma multiforme who, after
surgery, were randomized to radiotherapy versus HSV-tk/ganci-
clovir gene therapy, followed by radiotherapy. No significant
differences were observed between the 2 treatment arms, possibly
pointing to the prematurity of the attempt (Rainov, 2000). 
Although initially gene transfer has been envisioned by many as
being able to eradicate cancer as a single modality, a principle that
has recently emerged is the value of combining gene transfer with
traditional anticancer modalities such as chemotherapy and radia-
tion therapy. That has been nicely demonstrated for the replicating
adenovirus ONYX-015 in combination with 5-FU chemotherapy
(Heise et al, 1997) and confirmed in a clinical trial in head and
neck patients where viral monotherapy led to objective responses
in only 15% of the patients as compared to 60% of the patients
when this treatment was combined with 5-FU/cisplatin chemo-
therapy (Khuri et al, 2000). Based on historic controls,
chemotherapy alone in this setting had only a 35% chance of
response. This principle is further investigated in an ongoing phase
III study, randomizing patients who have failed radiation therapy
for recurrent head and neck cancer between treatment with
ONYX-015 in combination with 5-FU/cisplatin versus 5-FU/
cisplatin alone. The mechanism of synergy has not been com-
pletely elucidated. It is possible that ONYX-015 is able to sensi-
tize infected and uninfected cells to chemotherapy-induced cell
death. EIA gene expression is an important chemosensitizer, and
this effect is independent of p53 in some models. As ONYX-015
expresses E1A in both p53-deficient and p53-functional cancerCancer gene therapy clinical trials 1435
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cells, this mechanism may account for the chemosensitization of
both tumour types in vitro. However, E1A expression does not
chemosensitize normal non-transformed cells. In addition, aden-
ovirus-induced cytokines such as tumour necrosis factors can act
as important chemosensitizers. Elucidation of the mechanisms
involved in the chemosensitization may allow enhancement of this
effect in future trials. 
Similarly, intratumoural administration of the replication defi-
cient p53 adenovirus, along with cisplatin chemotherapy, appears
to chemosensitize a variety of tumour cell lines (Nielsen et al,
1997) including lung cancer cells and tumours in vivo to the effect
of chemotherapy: 2/24 patients with refractory platinum non-
small-cell lung cancer exhibited partial responses and stable
disease was seen in 17 patients (Nemunaitis et al, 2000). This is
presumably the result of restoration of an apoptotic mechanism of
cell death in these cancer cells; in situ nick-end labelling assay
demonstrated increase in apoptosis in 79% of the patients. 
Combination of gene transfer with radiation therapy is also a
subject of ongoing evaluation. Based on encouraging preclinical
work, a phase I/II trial of radiation therapy in combination with 3
biweekly intratumoural injections of Ad p53 in patients with
locoregionally advanced non-small-cell lung cancer, achieved one
year progression-free survival of 45.5%, which is superior to
historic controls (Swisher et al, 2000). Similarly, the conditionally
replicating adenovirus ONYX-015 had a synergistic effect when
combined with radiation therapy in radiation-resistant glioma
xenografts (Georger et al, 2000). 
In summary, a significant amount of information has emerged from
cancer gene therapy clinical trials during the last 10 years. As a result
of this experience, when vector systems previously used in the clinic
are employed, demonstration of safety is no longer an adequate justi-
fication for clinical trials in the absence of preclinical data supporting
also the efficacy of the approach. In addition, for viruses already used
in the clinic, it is questionable if the traditional phase I design is an
appropriate means of determination of the phase II dose. It appears
that for both adenoviruses and retroviruses, the maximum number of
infectious particles delivered intratumourally is only limited by the
titres that can be produced. Different rules apply, however, when
intra-arterial or intravenous vector administration is contemplated, or
when novel replicating viral vectors are introduced to the clinic. In
these settings, safety has to be convincingly demonstrated. 
Correlative endpoints, including evaluation of expression of the
transferred genes, immunologic response to transgenes and vectors
(when appropriate), vector kinetics and assessment of viral replica-
tion, if replicating vectors are employed, are crucial in order to vali-
date the clinical utility of a given approach, in combination with
more traditional endpoints such as assessment of safety and efficacy. 
In addition, strict reporting requirements will have to be
followed in order to ensure the safety of patients participating in
clinical gene transfer studies. The National Institute of Health in
the United States is in the process of implementing additional
safeguards to better oversee safety aspects of clinical gene
therapy trials. The Department of Health and Human Services
reorganized the Office for Human Research Trials. A National
Human Research Protection Advisory Committee was estab-
lished and the Food and Drug Administration (FDA) created the
Office for Human Research Trials (Ready, 2001). While it
remains an ongoing challenge, there is gradually increasing
hope that new developments in the field of gene transfer,
including vector targeting, new vector systems, replicating
vectors, and novel transgenes, along with constructive use of
lessons learned in the recent past, will allow the safe and effi-
cient incorporation of gene transfer in the treatment of cancer. 
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